LABD inverse fund (3X inverse SPBIO), marked with time pivots and potential channel.
The plus or minus one-day on the Fibonacci counts, is well within acceptable limits.
There’s been so much focus on biotech because of the opportunity.
Trading congestion equals directional potential.
A good way to show that (downside) potential, is with the P&F chart of biotech IBB, below:
The initial projection targets the 120-area which is below the support levels at, 143 – 145. If penetrated, those support levels would likely become resistance to any upward retrace.
We’re about an hour to go before the regular open. LABD is trading flat to slightly higher.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
The two hits on the right side channel line provide confirmation of the trend.
An expanded version of the daily is below:
So far, we’ve had the blockage of the Suez Canal. Auto parts being sent to the bottom of the ocean off Japan. ‘Mysterious’ grain silo fires destroying harvested crops.
If transportation is shut down as a result of cyber attack, fuel pipelines off-line, no grease to lubricate the wheels or any number of other (planned … and don’t think there’re not) events, the last thing that’s going to help get anyone through, is a ‘stack’ of inedible metal.
It’s no secret this site’s been using the Biblical precedent of Genesis 41.
That is: Grain and Corn come first … then gold and silver.
The ‘stacking’ public has got this message reversed. Of course, this is not advice or a recommendation.
However, for those that can see, it’s so obvious the goal is ‘controlled demolition’ of the supply chain. All of it.
We’ll put everything back to ‘normal’ if you just get injected.
Meanwhile, biotech IBB, and SPBIO, have both posted a new daily low.
IBB is poised to penetrate the resistance area identified in this update, and come back to test the wide bar.
If that happens, we have a Wyckoff up-thrust in play. More analysis of biotech to follow.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
In a situation that’s straight out of any typical trading text: ‘When a market goes into a throw-over and then enters back into the range, it’s a classical analysis sell signal’ (not advice, not a recommendation).
That’s where Moderna (MRNA) is now.
Moderna’s the ‘chief cook and bottle washer‘ for the world-wide kabuki theater. So, we’re using it as a proxy for the biotech sector as a whole.
Separately, biotech index IBB, is retracing but has not posted a new daily low.
Inverse SPBIO fund LABD, has formed an hourly reversal bar and looks to be forming a daily reversal bar. As of this update, it has yet to post a new daily high.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Starting with the (unmarked) weekly chart of IBB below, we see the current upside breakout.
We’re going to invert the chart and label the ‘resistance’ as ‘support’.
Inverting charts is a technique discovered years ago in a long since forgotten trading text; possibly Dr. Elder’s
The ‘inverting exercise’ is to help eliminate chart bias.
For example: If you see bullish no matter which way you turn the chart … there’s a preconditioned bias that’s affecting decisions.
On to the inverted chart:
What we see above, is a typical Wyckoff spring set-up.
Price action has decisively penetrated support (resistance on the regular chart) and is now eroding.
The distance of the trading range is shown as the dashed line.
Look at the near perfect symmetry.
Putting the range bar at the top of the trading range gives a measured move … right into resistance (support) of the next range.
Price typically moves down, two or three times as fast, as it moves up.
That’s why the professional speculators (throughout trading history) prefer down markets. If there are profits, they show up a lot faster.
Fundamentals:
Enormous pressure continues to build against the sector. You have to wonder what’s it’s going to take for the big break.
Just out last night, was this report from ZeroHedge. The CDC is having an emergency meeting to discuss ‘heart inflammation’ problems with the injections.
Let’s start there with a ‘safe’ topic and not discuss things like ‘dead within 15-minutes’ of injection.
Or maybe this one: A bloke gets himself injected and nearly kills two people with his truck a few minutes later.
The date on the video is June 11th. People are still getting this thing even with so much adverse reaction (death) information available?
The two narrating have a good point. What happens when a pilot is on final approach in bad weather, when he suddenly goes into an ‘event’.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Looking at the weekly close chart, we can see the wide range.
In addition, there’s a significant bullish divergence that (technically) gives the dollar, UUP, enough energy to test the top of that range; a potential that’s completely opposite the current narrative.
A this juncture, silver, gold and the miners are still correlated.
Yesterday, a potential top and reversal in miners GDX, was identified. Today, it appears to be hovering and looking unsure of its direction.
GDX has not posted a new daily high or low as of this update.
A sustained dollar rally (along with the bond market?) would be unexpected given what seems to be apoplectic hyperinflation ranting.
Separately, in biotech, the market (IBB) has stalled to the upside in a higher than expected test. Inverse fund LABD, made a new daily low and it too, has stalled.
Downward thrust energy on LABD is dissipating.
Technical update for biotech, planned for tomorrow … market permitting.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
It’s about 80-minuts before the close and already, IBB’s printed more single day volume than in the past four years.
There must have been a huge number of stops at the resistance area for price action to launch so decisively.
Now, as we get near the close we’ll see if it was just short covering, or if there’s really some kind of demand to hold and move prices higher.
The 4-Hour chart (below) shows a potential reversal as we head into the closing hour.
It’s the trader’s discretion on how to interpret and position (if warranted) in this environment. This site does not make recommendations.
However, based on the technical and fundamental data provided over the past year, we’re expecting at some point, a complete collapse of the sector; bottoming-out sometime in mid to late October, this year; not advice, not a recommendation.
If IBB continues to push decisively upward from here, meaning, tomorrow’s session is follow-through action, it will most likely (but not fore sure) invalidate the ‘collapse’ scenario.
We’re at the danger point
One of many other factors helping the bearish assessment is the release of this report:
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Well, none almost, other than to be reminded the powers that be have absolute contempt for those that aren’t in their global club.
You have to wonder, what’s next? Maybe it’s time for the (fake, or real) alien invasion.
Maybe we’ll have a few more ‘planned’ cyber attacks … who knows?
Meanwhile, back at the ranch, it’s more than a bit interesting the biotech sector with its quarterly reversal, weak 23.6% retrace, and now continuing downside (so far), is not a major topic of discussion.
This morning, Moderna’s (MRNA) attempting a breakout. It won’t look so good if it can’t close higher for the day.
The last update showed MRNA, insiders bailing out.
SPBIO looks to be establishing or confirming a downside trend-line. More on that if/when there’s confirmation.
Stay Tuned
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
